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Abstract
Background: The diagnosis of tuberculosis remains difficult. This study aimed to assess performance of interferon-gamma
release assay (IGRA) in diagnosis of active tuberculosis (ATB) with pulmonary and extrapulmonary involvements, and to
determine the diagnostic role of IGRA (T-SPOT.TB) and tuberculin skin test (TST) in BCG-vaccinated population.
Methods and Findings: Two hundred twenty-six ATB suspects were recruited and examined with T-SPOT.TB. Among them,
fifty-two and seventy-six subjects were simultaneously tested by TST with 5TU or 1TU of purified protein derivative (PPD).
The sensitivity of T-SPOT.TB was 94.7% (71/75), comparable in pulmonary and extrapulmonary disease groups (95.6% vs.
93.3%, P.0.05), while the specificity was 84.10% (90/107) but differed in two groups (69.2% vs. 88.9%, P=0.02). Compared
to T-SPOT.TB, TST with 5TU-PPD showed less sensitivity (92.3% vs. 56.4%) and specificity (84.6% vs. 61.5%) (both P,0.01);
the sensitivity of TST with 1TU-PPD was 27.8%, and despite its specificity identical to T-SPOT.TB (both 82.8%) positive
predictive value (PPV) was only 33.3%. By combining T-SPOT.TB with TST (1TU), the specificity rose to 95%, but the PPV
stayed unchanged.
Conclusions: IGRA could function as a powerful immunodiagnostic test to explore pulmonary and extrapulmonary TB, while
TST failed to play a reliable or auxiliary role in identifying TB disease and infection in the BCG-vaccinated population.
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Introduction
In recent decades, the burden of tuberculosis (TB) has been
increasingly falling on developing countries. Although the TB
vaccine Bacille Calmette-Gue ´rin (BCG) is broadly vaccinated and
DOTS (Directly Observed Treatment, Short-course) programme
is well implemented, the incidence rate of active tuberculosis
(ATB) in China has been doubled over ten years (39.03/100,000
in 1999 vs. 81.09/100,000 in 2009), with the death rate soaring 7-
fold in this decade [1]. Despite incorporation of clinical,
radiological, pathological and microbiological examinations,
diagnosis of ATB can still be difficult. Conclusive diagnostic tests
microbial culture and smear for acid-fast bacilli are not sensitive
enough to identify all the active cases. Moreover, for extrapulmo-
nary tuberculosis (EPTB), less specific clinical clues can be used
and invasive procedures or low bacterial load leads to less chance
to establish the pathological or microbiologic diagnosis [2,3].
Immunoassays capable of detecting the host’s immune response
specific to TB causative agent Mycobacterium Tuberculosis (M.TB) has
become an alternative diagnostic aid for ATB [2]. Long-time-used
tuberculin skin test (TST) has encountered considerable difficul-
ties, mainly due to the disability of its mixed antigens tuberculin
purified protein derivative (PPD) to distinguish the true ATB
patients from those vaccinated with BCG or sensitized with
Nontuberculous Mycobacteria (NTM) [4]. Recently, interferon-gamma
release assays (IGRAs) have shown their superior diagnostic
performance over TST [4,5,6,7,8,9] by using at least two specific
antigens (ESAT-6 & CFP 10) present exclusively in M.TB but
absent in BCG strains and most NTM [9,10]. Herein, we put
ELISpot-based-IGRA (T-SPOT.TB) into test to examine how it
works especially for identifying EPTB in comparison with
pulmonary tuberculosis (PTB). Meanwhile, we compared the
performance between IGRA and TST with two currently used
doses (5TU; 1TU) to elaborate whether TST is still strong enough
to carry on the diagnostic role in ATB for the TB-epidemic and
BCG vaccinated populations.
Methods
This study got ethical approval from Huashan Institutional
Review Board (HIRB), the ethics reviewing committee of Huashan
Hospital, Fudan University. Informed consent was obtained from
all the participants in the written form.
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A prospective study was conducted in HIV-negative subjects
with suspicion of active TB collected between September 2008 and
September 2009. A total of 226 patients from China were tested
with T-SPOT.TBH at enrollment, together with routine clinical,
microbiologic, pathological and radiographic examinations. Indi-
viduals were excluded if they have received .30 days of anti-
tuberculosis therapy or if they have received the treatment within
one year prior to enrollment; those treated for one year or longer
before enrollment were otherwise involved. All patients were
vaccinated with BCG at early childhood or during adolescence.
Major clinical characteristics of recruited subjects were summa-
rized in Table 1.
After a follow-up of at least 3 months, by January 2010, 44
patients were excluded from the study, among which 10 died
before final diagnosis, 17 lost follow-up, and 17 had no final
diagnosis. The remaining 182 patients were ultimately included for
T-SPOT.TB analyses (Figure 1), of which 128 consented to
perform TST concurrently, 76 with 1TU-PPD, and 52 with 5TU-
PPD.
Definitions and Diagnosis
TB suspects were defined as patients whose clinical or
radiographic manifestations were consistent with active TB [11],
but lack of culture or pathological evidence for confirmative
diagnosis. Finally, they had one of three diagnoses: (1) ‘culture/
biopsy-confirmed ATB’ if final diagnoses were made on the
positive culture of M. TB from sputum or the presence of caseating
granuloma in biopsy specimen; (2) ‘clinical ATB’ if patients, whose
clinical presentations were consistent with ATB but lack of
bacterial/pathological corroborative evidence, presented manifest
clinical or radiographic responses to anti-TB treatment; (3) ‘no
ATB’ if the patients did not meet the above two criteria and their
clinical presentations diminished spontaneously or following non-
TB-related treatment.
T-SPOT.TB assay
The T-SPOT.TB test was performed following the instructions
of the assay kit (Oxford Immunote Ltd., Oxford, UK). Briefly,
peripheral blood mononuclear cells (PBMCs) were isolated and
incubated with two antigens (ESAT-6 in panel A; CFP-10 in panel
B). The procedure was performed in the plates pre-coated with
anti-interferon-c antibodies at 37uC for 16 to 20 hours. After
Table 1. Clinical characteristics of 182 patients with
suspected active TB.
Characteristics
Total
(n=182)
ATB
(n=75)
No ATB
(n=107)
Age, median (range), yr 52 (14–87) 41(16–84) 51(14–87)
Male/Female 87/95 43/32 44/63
Presence of TB history 13 1 12
Presence of TB contact 11 5 6
TB scar in chest radiographs 23 8 15
Immunocompromised conditions 13 1 12
Liver cirrhosis 1 0 1
Chronic renal failure 2 1 1
Leukemia 2 0 2
Idiopathic myelofibrosis 1 0 1
Hemophagocytic syndrome 1 0 1
Low CD4 count 1 0 1
Immunosuppressive drugs 5 0 5
ATB: active tuberculosis; No ATB: diagnosis other than active tuberculosis.
doi:10.1371/journal.pone.0032652.t001
Figure 1. Flowchart of the study population. A total of 226 subjects suspected to have active tuberculosis (ATB) were recruited and 182 were
eligible to be included in the final analyses. The analyses were composed of two parts: a study on the diagnostic performance of the T-SPOT.TB on
pulmonary and extrapulmonary ATB, and a study comparing the performance between T-SPOT.TB and TST with a dose of 1TU-PPD or 5TU-PPD. ATB,
active tuberculosis; no ATB, final diagnosis excluded active tuberculosis.
doi:10.1371/journal.pone.0032652.g001
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and chromogenic substrate, spots were scored using an automated
ELISPOT plate reader (AID-Gmb-H, Germany).
TST
TST was tested on the patients’ volar surface of a forearm, by
intradermal injection of 1 tuberculin unit (TU) of PPD-S (Statens
Seruminstitut, Copenhagen, Denmark) (n=76) or 5TU of PPD
(n=52). The size of the induration was read at 72 h. Based on the
transverse diameter of induration, the cut-off value was deter-
mined as follows: induration ,10 mm denoted as negative (2);
induration $10 mm as positive (+).The TST and T-SPOT.TB
were all conducted simultaneously.
Statistical analyses
Sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), likelihood ratio positive (LR+), and
likelihood ratio negative (LR2) were calculated to evaluate
diagnostic performance for the T-SPOT.TB and TST. Ninety-
five percent confidence intervals (95%CI) were estimated accord-
ing to the binomial distribution. Significance was inferred for
P,0.05. Concordance between the results of TST and T-
SPOT.TB was assessed using k coefficients (k.0.75, excellent
agreement; k,0.4, poor agreement; 0.75$k$0.4, fair to good
agreement). Analyses were performed using statistical software
packages (Stata version 9; StataCorp; College Station, TX).
Results
Clinical characteristics
Of 182 ATB suspects with valid T-SPOT.TB results, 71 were
categorized into pulmonary disease group and 111 in extrapul-
monary disease group (Figure 1). Patients with EPTB concur-
rently with documented PTB were included into PTB group.
Eventually, 107 patients excluded ATB and 75 were diagnosed as
ATB. Of the latter, 45 were confirmed with culture/biopsy
evidences, and 30 as probable ATB cases with clinical evidences.
Clinical characteristics of 182 patients are shown in Table 1. The
distribution of affected extrapulmonary organs was highly
heterogeneous which involved central nervous system, peripheral
lymph nodes, pleura, bones, genitourinary system, gastrointesti-
nal tract, and skin (Table 2).
Diagnostic performance of T-SPOT.TB: overall and
stratified by disease site
The diagnostic values of T-SPOT.TB for the 182 subjects are
presented in Table 3. The overall sensitivity and specificity were
94.70% (95%CI, 86.9%–98.5%), 84.10% (95%CI, 75.8%–
90.5%), respectively. There was no significant difference in the
sensitivity between the ‘confirmed ATB’ cases (93.3%, 42/45) and
the ‘clinical ATB’ cases (96.7%, 29/30; P.0.05). PPV, NPV, LR+
and LR2 of the T-SPOT.TB were 80.70%, 95.70%, 5.96 and
0.06, respectively, and the prevalence was 41.2% in the cohort
(Table 3).
The stratified performance by the site of disease is shown in
table 2. Among the 71 patients with pulmonary involvement, T-
SPOT.TB was positive in 43 of 45 ATB cases, with a sensitivity of
95.6% (95%CI: 84.9%–99.5%) which did not differ significantly
from the sensitivity of 93.3% (95%CI: 77.9%–99.2%) in extra-
pulmonary disease group (28/30). However, the specificity was
69.2% (95%CI: 48.2%–85.7%) in pulmonary disease group, while
a higher specificity was observed in extrapulmonary disease group
(88.9%; 95%CI: 80.0%–94.8%; P=0.017). The results of
extrapulmonary disease group were further stratified by affected
sites. Notably, apart from pleura (50%; 1/2) and abdomen
tuberculosis (83.3%; 5/6), the sensitivity of T-SPOT.TB was as
high as 100% for the most affected sites, while the specificity
ranged from 60% to 97% (Table 2).
Risk factors for false-positive outcomes in T-SPOT.TB:
overall and stratified by disease site
A number of risk characteristics of patients associated with false-
positive and false-negative results were evaluated by multivariate
logistic regression. Age$median age (46-year)’ and ‘history of
prior TB’ were turned out to be two independent risk factors
related to false-positive outcomes. Odds ratio (OR) between false-
positives and true-positives for overall, and in pulmonary and
extrapulmonary groups are present individually in Table 4. For
the risk factor of ‘age$median age’, the overall OR was 5.09
(95%CI 1.28–20.25; P=0.021) whereas 10.71 (95%CI 1.21–
Table 2. Comparison of performance of T-SPOT.TB assay in pulmonary and extrapulmonary tuberculosis.
Site of disease ATB n No ATB n T-SPOT.TB(+) n T-SPOT.TB(2) n Sensitivity% (95%CI) Specificity% (95%CI)
Pulmonary disease 45 26 43 18 95.6%(84.9%–99.5%)* 69.2%(48.2%–85.7%)**
Extra-pulmonary disease 30 81 28 72 93.3%(77.9%–99.2%) 88.9%(80.0%–94.8%)
Central nervous system 12 26 12 23 100% 88.5%
Lymphadenitis 3 0 3 0 100% N/A
Pleurisy disease 2 0 1 0 50% N/A
Abdominal disease
(liver, pancreas, spleen)
6 4 5 4 83.3% 100%
Genitourinary disease 2 6 2 4 100% 66.7%
Bone disease 3 5 3 3 100% 60%
Skin disease 2 6 2 5 100% 83.3%
Other sites 0 33 0 34 N/A 97.1%
Total 75 107 71 90 94.7%(86.9%–98.5%) 84.1%(75.8%–90.5%)
ATB, active tuberculosis; No ATB, diagnosis other than active tuberculosis;
*P.0.05;
**P=0.017.
doi:10.1371/journal.pone.0032652.t002
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for ‘history of prior TB’, OR for overall was 10.06 (95%CI 1.61–
62.75; P=0.013), but OR value could not be calculated in
pulmonary group because no false-positive had TB history in this
group. By contrast, extrapulmonary disease group showed invalid
OR for both risk factors, with 95%CI crossed 1 and P value .0.05
(Table 4). Additionally, No risk factors to false-negatives were
elicited.
Comparisons between T-SPOT.TB and TST with two
doses of PPD
In search of the best strategy for active tuberculosis immunodi-
agnosis, we examined subjects with TST using two PPD strengths:
76 subjects with 1 TU PPD (abbreviated to ‘TST
1TU-PPD’), and 52
with 5 TU (TST
5TU-PPD). T-SPOT.TB was simultaneously applied
to the two cohorts. The diagnostic values of ‘TST
1TU-PPD vs. T-
SPOT.TB’ and ‘TST
5TU-PPD vs. T-SPOT.TB’ were listed in
Table 5. A statistically significant difference in sensitivity was found
between TST
1TU-PPD and T-SPOT.TB (27.8% vs. 94.4%;
P,0.001), but no difference in specificity was observed as they
shared the same value (both 82.8%, P=1.000). The PPV and NPV
was 33.3% and 78.7% for TST
1TU-PPD, and was 63.0% and 98.0%
for the T-SPOT.TB, respectively. TST
5TU-PPD significantly differed
from T-SPOT.TB both in sensitivity (56.4% vs. 92.3%, P=0.001)
and specificity (61.5% vs. 84.6%, P=0.0078). The PPV and NPV
was 81.5% and 32.0% for TST
5TU-PPD, and was 94.7% and
78.6% for the T-SPOT.TB, respectively. When the concordance
was assessed by kappa coefficient (k), poor agreement was
shown between either comparison, 67.11% for ‘T-SPOT.TB vs.
TST
1TU-PPD’( k=0.19) and 63.46% for ‘T-SPOT.TB vs.
TST
5TU-PPD’( k=0.28).
Single and combination diagnostic test efficiency of T-
SPOT.TB and TST
In order to enlarge the features of immunoassays deviating
from ‘gold standard’ test, we plotted four basic diagnostic
parameters for two comparisons in figure 2, in which a true
positive/negative rate line and a false positive/negative rate line
were perpendicular to each other, and the shape of a test was
formed by connecting its four rates. A ‘gold standard’ test creates
a vertical line with 100% true-rates and zero false-rates, and the
‘fatter’ shape a test displays, the more deviation it gets. The most
prominent deviation in figure 2A was the false-negative rate
(72%) exceeded the true-positive rate (28%) for TST
1TU-PPD, and
the considerable loss of both true-positive and true-negative rates
contributed to a nearly symmetric diamond shape for TST
5TU-
PPD in figure 2B. By contrast, T-SPOT.TB remained a ‘slim’
figure with a slight deviation toward the pole of false-positive in
figure 2A and 2B.
We further estimated if diagnosis efficiency could be improved
when two tests were combined by parallel and serial testing
algorithms. The graphic illustration (Figure 2C and 2D) showed
that parallel testing did not bring the sensitivity of T-SPOT.TB up
when combining with TST
1TU-PPD or it increased from 92% to
95% when combining with TST
5TU-PPD,but both at the expense of
a considerable increase in false-positive rate, resulting in a similar
shape as T-SPOT.TB but ‘fatter’ (Figure 2C and 2D). On the
other hand, serial testing increased the specificity of T-SPOT.TB
from 83% to 95% when combining TST
1TU-PPD, but did not
make any improvement when combing with TST
5TU-PPD.
Meanwhile, the serial PPV was unchanged and decreased by
3.4% in the two combinations respectively (Table 6).
Discussion
Performance characteristics of T-SPOT.TB
Our study revealed a 94.7% overall sensitivity of T-SPOT.TB
for detecting ATB which was parallel with our previously
published data [12] and within the ranges recently reported
elsewhere [8,13]. Extrapulmonary tuberculosis (EPTB) reported
by different countries varies from 15% to 25% in the ATB cases
[14]. However, the corroborative epidemiological data for EPTB
is rarely available in most TB-endemic country due to diagnostic
difficulties. We explored, for the first time, the role of the IGRA in
detecting EPTB in Chinese patients. T-SPOT.TB turned out to be
sensitive equally in determining PTB and EPTB (95.6% vs. 93.3%;
P.0.05). In the 111 patients with extrapulmonary involvement, of
note was a 100% sensitivity seen in the most investigated sites
(Table 2).
Table 3. Diagnostic performance of T-SPOT.TB assay in 182
active tuberculosis suspects.
Parameter Value 95%CI
Sensitivity, % (n) 94.70 (71/75)* 86.9–98.5
Specificity, % (n) 84.10 (90/107) 75.8–90.5
PPV, % (n) 80.70 (71/88) 70.9–88.3
NPV, % (n) 95.70 (90/94) 89.5–98.8
LR+ 5.96 3.84–9.24
LR2 0.06 0.02–0.17
Prevalence, % (n) 41.2 (75/182) 34.0–48.7
PPV, positive predictive value; NPV, negative predictive value; LR+, likelihood
ratio for positive test; LR2, likelihood ratio for negative test.
*The sensitivity for ‘culture/biopsy-confirmed’ subgroup was 93.3% (42/45),
with a 95%CI of 81.7%–98.6%; for ‘clinical ATB group’ was 96.7% (29/30), with
the 95%CI of 86.8%–99.9%; P.0.05.
doi:10.1371/journal.pone.0032652.t003
Table 4. Logistic regression analyses of risk factors leading to false-positive results in T-SPOT.TB assay.
Pulmonary disease Extrapulmonary disease Total
Risk factor OR 95%CI P value OR 95%CI P value OR 95%CI P value
Age$median age* 10.71 1.21–94.95 0.009 3.13 0.51–19.04 0.216 5.09 1.28–20.25 0.021
History of prior TB N/A** 4.8 0.35–65.76 0.240 10.06 1.61–62.75 0.013
OR: odds ratio of risk factors between false positive and true positive results.
*Median age: 46 years old, the median age calculated in patients positive for T-SPOT.TB.
**N/A: the value could not be calculated because no false positive subject had TB history in pulmonary disease group.
doi:10.1371/journal.pone.0032652.t004
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(80.70%) than most data elicited from the developed countries
[8,13] which may suggest relatively higher prevalence of latent
tuberculosis infection (LTBI) in China. For better understanding
the causes and likelihood of false-positives in the population tested,
we analyzed risk factors leading to false-positives (Table 4). The
Table 5. Comparisons of performance between ‘TST
1TU PPD vs. T-SPOT.TB’ and ‘TST
5TU PPD vs. T-SPOT.TB’.
TST
1TU PPD vs. T-SPOT.TB (n=76) TST
5TU PPD vs. T-SPOT.TB (n=52)
Parameters TST
1TU PPD T-SPOT.TB TST
5TU PPD T-SPOT.TB
Sensitivity, % (n) 27.8 (5/18) 94.4 (17/18)
a 56.4 (22/39) 92.3 (36/39)
C
Specificity, % (n) 82.8 (48/58) 82.8 (48/58)
b 61.5 (8/13) 84.6 (11/13)
d
PPV 33.3 (5/15) 63.0 (17/27) 81.5 (22/27) 94.7 (36/38)
NPV 78.7 (48/61) 98.0 (48/49) 32.0 (8/25) 78.6 (11/14)
LR+ (95%CI) 1.61 (0.63–4.10) 5.48 (3.08–9.73) 1.47 (0.70–3.08) 6.00 (1.67–21.54)
LR2 (95%CI) 0.87 (0.64–1.19) 0.07 (0.01–0.45) 0.71 (0.41–1.24) 0.09 (0.03–0.28)
Prevalence, % 23.7 (18/76) 75.0 (39/52)
Concordance,% 67.11 63.46
Kappa value 0.1866 0.2841
TST: tuberculin skin test; PPV, positive predictive value; NPV, negative predictive value; LR+, likelihood ratio for positive test; LR2, likelihood ratio for negative test.
a: P=0.0005;
b: P=1.000;
c: P=0.001;
d: P=0.0078.
doi:10.1371/journal.pone.0032652.t005
Figure 2. The deviation features of the T-SPOT.TB, TST in single or combination way. The deviation from the gold standard test was
compared between T-SPOT.TB and TST
1TU PPD (A), T-SPOT.TB and TST
5TU PPD (B), and between the combination in parallel and serial way for these two
comparisons (C, D). The north, south, east and west poles in each panel represented 100%of the true-positive rate, true-negative rate, false-positive
rate, and false-negative rate, respectively, and each observed rate located between the top poles of the axes (100%) and the central origin (0%). In A
and B, the shape formed by connecting the diagnostic rates of T-SPOT.TB was outlined by the dark lines and the shape of TST were filled with grey
color. In C and D, parallel testing was outlined by dashed lines, and serial testing by dotted lines.
doi:10.1371/journal.pone.0032652.g002
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false-positives was about 5 or 10 times higher than the odds
leading to true-positives. Aging and having TB history are known
to be the important factors in the individualized clinical risk
assessment for LTBI. Similarly, a discrepancy in specificity
between pulmonary and extrapulmonary groups (69.2% vs.
88.9%; P=0.017) can also be explained by the presence of
significant difference in OR between groups. OR (10.71) for ‘over-
median age’ factor in pulmonary group inferred a nearly 11-fold
risk increase caused by the factor to yield a false-positive, whereas
the risk factor of age was not related to false-positives in
extrapulmonary group.
IGRAs were designed for identification of LTBI and high
prevalence of TB may increase the ‘false-positives’ of IGRAs such
that a considerable portion of cases with LTBI could be
misrecognized as ATB if relying on IGRAs. Moreover, comparing
with the specificity, PPV (80.70%) and LR+ (5.96), the sensitivity,
NPV (95.7%) and LR2 (0.06) strongly indicated IGRAs are better
at ruling out ATB than ruling it in. Thus, the real role of IGRAs in
high TB-prevalence countries would be appropriate for ruling out
a diagnosis of TB.
Comparing immunodiagnostic strategy for patients with
the history of BCG vaccination
The TST suffers from the low specificity and sensitivity when
tested on population with high BCG-vaccination coverage and
high TB prevalence. TST using a standard dose of 5 tuberculin
units (TU) PPD has been widely used, but there is always a
disagreement about its role in vaccinated people. The US
recommends the interpretation of TST irrespective of prior
BCG vaccination, resulting in considerable overdiagnosis of LTBI,
while the UK strategy probably misdiagnoses LTBI cases due to
the recommendation that the serial TST be contraindicated for
BCG-vaccinated persons and IFN-c testing be used to help
interpret positive TST results [15,16,17]. For a country having
serious TB burden and urgent task to treat active TB, we have to
know how much we can rely on this test and how to arrange our
best immunodiagnostic strategy.
The study revealed that the sensitivity (56.4%) and specificity
(61.5%) for TST with 5TU-PPD (TST
5TU-PPD) were both beneath
the performance of T-SPOT.TB (Table 5) and lower than a
roughly 70% sensitivity and 66% specificity reported by two recent
comprehensive reviews [8,18]. Meanwhile, a dose of 1 TU PPD
(TST
1TU-PPD) has long been used to rule in TB cases in some
BCG-vaccinated counties like China. Its reliability faces the
arguments for its strong specificity and against the weak sensitivity.
They were both confirmed by our study (Table 5). Interestingly, a
nearly symmetric ‘short’ and ‘fat’ figure for TST
5TU-PPD and ‘shot’
in sensitivity but getting ‘fat’ toward false-negative for TST
1TU-PPD
were graphically presented in figure 2. By contrast, T-SPOT.TB
remained ‘thin’ with only a slight growth in false-positive rate
presumably reflecting the LTBI prevalence.
TST
1TU-PPD showing a specificity numerically identical to the
T-SPOT.TB was supposed to identify the presumed LTBI cases
like T-SPOT.TB did, and those cases should be simultaneously
positive for both tests. However, our observation indicated only
30% of false-positives in one test were also positive for the other. It
was very likely that the reasons leading to false-positive for T-
SPOT.TB and TST
1TU-PPD may not be same: based on our study
and other literatures [19,20,21], T-SPOT.TB exhibited the ability
to detect LTBI, and TST on the other hand was very likely to
falsely recognize those vaccinated with BCG or sensitized with
NTM even at the small dose of PPD instead of recognizing LTBI.
Thus, the dose of 1TU-PPD appeared insensitive to elicit the
detectable immune response in people with either TB infection or
disease.
We further investigated whether the performance of T-SPOT.
TB can be improved by combining with either TST
1TU-PPD or
TST
5TU-PPD. A parallel combination test is usually expected to
increase sensitivity, , but we found that even at the expense of a big
reduction in specificity, the sensitivity of T-SPOT.TB did not
increase by parallel combining with TST
1TU-PPD (figure 2A and
2C), because the false-negative number upon combination failed
to decline (Table 6). Obviously, TST
1TU-PPD could not help
increase true-negatives by parallel testing due to its low sensitivity.
On figure 2B and 2D, parallel and serial testing both displayed a
‘fatter’ feature than T-SPOT.TB with only growth in sensitivity
from 92% to 95%, in that TST
5TU-PPD helped rule in 1 ATB case
(Table 6). The only big improvement in two combination ways
was the specificity from 83% to 95% after serial combining the T-
SPOT.TB with TST
1TU-PPD, but along with a paradoxically
unchanged PPV. A serial combination is expected to increase
specificity and PPV by reducing false positives when both tests
must be positive. However, a greater decrement in true-positives
than in false-positives after combination suggested that the
limitation of TST to identify the true-positives compromised the
Table 6. The effect of parallel and serial testing on sensitivity, specificity and predictive values for T-SPOT.TB and TST in two
comparisons.
Test Sensitivity % (n) Specificity % (n) PPV % (n) NPV % (n)
TST
1TU PPD 27.8 (5/18) 82.8 (48/58) 33.3 (5/15) 78.7 (48/61)
T-SPOT.TB 94.4 (17/18) 82.8 (48/58) 63.0 (17/27) 98.0 (48/49)
T-SPOT.TB and TST
1TU PPD (parallel)
a 94.4 (17/18) 70.7 (41/58) 50.0 (17/34) 97.6 (41/42)
T-SPOT.TB and TST
1TU PPD (serial)
b 27.8 (5/18) 94.8 (55/58) 62.5 (5/8) 80.9 (55/68)
TST
5TU PPD 56.4 (22/39) 61.5 (8/13) 81.5 (22/27) 32.0 (8/25)
T-SPOT.TB 92.3 (36/39) 84.6 (11/13) 94.7 (36/38) 78.6 (11/14)
T-SPOT.TB and TST
5TU PPD (parallel)
a 94.9 (37/39) 61.5 (8/13) 88.1 (37/42) 80.0 (8/10)
T-SPOT.TB and TST
5TU PPD (serial)
b 53.8 (21/39) 84.6 (11/13) 91.3 (21/23) 37.9 (11/29)
a, two tests were combined in a ‘parallel’ way that took a positive result when either test was positive and a negative result when both negative.
b, two tests were combined in a ‘serial’ way that took a positive result when both test was positive and a negative result when either negative. The two tests were
performed simultaneously and the word ‘serial’ only indicated the combination fashion usually done. PPV, positive predictive value; NPV, negative predictive value.
doi:10.1371/journal.pone.0032652.t006
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determine true active tuberculosis.
There were some noteworthy limitations of this study. Despite
no difference in the sensitivity of T-SPOT.TB between the
culture/biopsy-confirmed (n=45) and clinical probable ATB
(n=30) groups, inclusion of those probable cases in the true
ATB group may bias the performance for both T-SPOT.TB and
TST and their comparisons. Besides, unbalanced factors of age
and TB history between comparative groups may also cause study
bias, The more subjectives were expected to involve into such
investigations.
In conclusion, the TST played a prominent part in the detection
of tuberculosis, but its contribution has been on the wane as other
immunoassays came into use with superior diagnostic performance
over it. This study demonstrated that T-SPOT.TB is a promising
tool for diagnosing tuberculosis with pulmonary and extrapulmo-
nary involvement. Moreover, not only cannot TST take major
part in immunodiagnosis of ATB, but it was not supported by our
study that combining TST with small or regular dose of PPD
would become a routine optimized immunodiagnostic strategy in
the population with high TB-prevalence and massive BCG-
vaccination. We highly recommend that IGRAs should be tested
as first priority to diagnose LTBI and ATB for those populations, if
applicable.
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